BRPI0416950A - métodos para remover vìrus de uma composição do fator vii lìquida, para inativar vìrus em uma composição do fator vii lìquida, e para eliminar em alto nìvel a presença de vìrus ativos em uma composição do fator vii lìquida - Google Patents

métodos para remover vìrus de uma composição do fator vii lìquida, para inativar vìrus em uma composição do fator vii lìquida, e para eliminar em alto nìvel a presença de vìrus ativos em uma composição do fator vii lìquida

Info

Publication number
BRPI0416950A
BRPI0416950A BRPI0416950-6A BRPI0416950A BRPI0416950A BR PI0416950 A BRPI0416950 A BR PI0416950A BR PI0416950 A BRPI0416950 A BR PI0416950A BR PI0416950 A BRPI0416950 A BR PI0416950A
Authority
BR
Brazil
Prior art keywords
viruses
liquid factor
factor composition
liquid
composition
Prior art date
Application number
BRPI0416950-6A
Other languages
English (en)
Inventor
Jesper Christense
Erik Halkjaer
Turid Preuss
Thomas Budde Hansen
Lene Vaedele Madsen Tomoda
Nina Johansen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0416950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0416950A publication Critical patent/BRPI0416950A/pt
Publication of BRPI0416950A8 publication Critical patent/BRPI0416950A8/pt
Publication of BRPI0416950B1 publication Critical patent/BRPI0416950B1/pt
Publication of BRPI0416950B8 publication Critical patent/BRPI0416950B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODOS PARA REMOVER VìRUS DE UMA COMPOSIçãO DO FATOR VII LìQUIDA, PARA INATIVAR. VìRUS EM UMA COMPOSIçãO DO FATOR VII LìQUIDA, E PARA ELIMINAR EM ALTO NìVEL A PRESENçA DE VìRUS ATIVOS EM UMA COMPOSIçãO DO FATOR VII LìQUIDA". A presente invenção diz respeito a um novo método para melhorar a segurança viral de composições de Fator VII líquidas, em particular aquelas que compreendem polipeptídeos do Fator VII ativos (um polipeptídeo do Fator VIla).
BRPI0416950A 2003-12-01 2004-12-01 métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida. BRPI0416950B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301775 2003-12-01
DKPA200301775 2003-12-01
PCT/EP2004/053206 WO2005054275A2 (en) 2003-12-01 2004-12-01 Nanofiltration of factor vii solutions to remove virus

Publications (4)

Publication Number Publication Date
BRPI0416950A true BRPI0416950A (pt) 2007-02-13
BRPI0416950A8 BRPI0416950A8 (pt) 2019-01-22
BRPI0416950B1 BRPI0416950B1 (pt) 2019-05-28
BRPI0416950B8 BRPI0416950B8 (pt) 2021-05-25

Family

ID=34639198

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416950A BRPI0416950B8 (pt) 2003-12-01 2004-12-01 métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida.

Country Status (14)

Country Link
US (8) US20070142625A1 (pt)
EP (3) EP2275432A1 (pt)
JP (3) JP4874806B2 (pt)
KR (1) KR101234170B1 (pt)
CN (3) CN1890257A (pt)
AU (1) AU2004294403A1 (pt)
BR (1) BRPI0416950B8 (pt)
CA (1) CA2545474A1 (pt)
DK (1) DK1711513T3 (pt)
ES (2) ES2507091T3 (pt)
PL (1) PL1711513T3 (pt)
PT (1) PT1711513E (pt)
RU (1) RU2472804C2 (pt)
WO (1) WO2005054275A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874806B2 (ja) * 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
DE102005037824A1 (de) * 2005-08-08 2007-02-15 Zlb Behring Gmbh Neuartiges Virusreduktionsverfahren
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
KR20140022845A (ko) 2011-03-25 2014-02-25 제넨테크, 인크. 신규 단백질 정제 방법
MY195362A (en) * 2012-06-21 2023-01-16 Baxalta Inc Virus Filtration of Cell Culture Media
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины
KR102238133B1 (ko) * 2013-11-15 2021-04-09 제넨테크, 인크. 환경-친화적 세제를 사용한 바이러스 불활성화 방법
CN105435644A (zh) * 2014-09-29 2016-03-30 中国石油化工股份有限公司 一种纳滤膜及其制备方法
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100501A (en) 1960-12-23 1963-08-13 Crane Co Removable head and seat ball valve construction
JPS6033009B2 (ja) * 1978-12-29 1985-07-31 三菱電機株式会社 マイクロ波発振装置
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
JP3459416B2 (ja) 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5677162A (en) * 1995-05-01 1997-10-14 New York Blood Center, Inc. Method for activating prothrombin to thrombin
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
EP0860444A1 (en) 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
AT407159B (de) * 1997-06-13 2001-01-25 Immuno Ag Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
CN1284881A (zh) * 1997-11-05 2001-02-21 吉富制药株式会社 肝素辅助因子ⅱ制剂及其制备方法
FI106465B (fi) 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1282693B1 (en) 2000-05-03 2010-10-20 Novo Nordisk Health Care AG Human coagulation factor vii variants
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
IL154520A0 (en) 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
BR0114374A (pt) * 2000-10-02 2003-12-30 Novo Nordisk As Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
PL371800A1 (en) 2001-03-22 2005-06-27 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
ES2376694T3 (es) 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
EP2279755B1 (en) 2001-10-10 2014-02-26 ratiopharm GmbH Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF)
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
JP4516839B2 (ja) 2002-04-30 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体修飾因子としての４−アザステロイド誘導体
SI1499719T1 (sl) 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
RS20050051A (en) 2002-07-23 2007-06-04 Bio-Products & Bio Engineering Ag., Pharmaceutical active ingredient preparation and medicaments that contain thrombin or have a thrombin-generating capacity
ATE428440T1 (de) 2002-07-23 2009-05-15 Bio & Bio Licensing Sa Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel
US20060166874A1 (en) 2002-09-30 2006-07-27 Haaning Jesper M Fvii or fviia variants having increased clotting activity
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII

Also Published As

Publication number Publication date
WO2005054275A2 (en) 2005-06-16
JP2007537994A (ja) 2007-12-27
RU2472804C2 (ru) 2013-01-20
KR20070001887A (ko) 2007-01-04
WO2005054275A3 (en) 2005-09-09
JP4874806B2 (ja) 2012-02-15
KR101234170B1 (ko) 2013-02-18
US20070142625A1 (en) 2007-06-21
EP3594222B1 (en) 2022-08-03
EP2275432A1 (en) 2011-01-19
CN102351953A (zh) 2012-02-15
US20220064605A1 (en) 2022-03-03
EP1711513A2 (en) 2006-10-18
EP3594222A1 (en) 2020-01-15
CN1890257A (zh) 2007-01-03
US9102762B2 (en) 2015-08-11
ES2926359T3 (es) 2022-10-25
EP1711513B1 (en) 2014-07-02
DK1711513T3 (da) 2014-09-15
CN102351953B (zh) 2017-05-10
RU2006118024A (ru) 2008-01-10
US20190032026A1 (en) 2019-01-31
JP5666359B2 (ja) 2015-02-12
CA2545474A1 (en) 2005-06-16
US20170022482A1 (en) 2017-01-26
US20080274534A1 (en) 2008-11-06
PT1711513E (pt) 2014-10-02
US20200248150A1 (en) 2020-08-06
CN106916802B (zh) 2022-03-25
JP2011173889A (ja) 2011-09-08
ES2507091T3 (es) 2014-10-14
US20150299685A1 (en) 2015-10-22
US20120115204A1 (en) 2012-05-10
CN106916802A (zh) 2017-07-04
JP2012021007A (ja) 2012-02-02
BRPI0416950B1 (pt) 2019-05-28
BRPI0416950A8 (pt) 2019-01-22
AU2004294403A1 (en) 2005-06-16
PL1711513T3 (pl) 2014-12-31
BRPI0416950B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0416950A (pt) métodos para remover vìrus de uma composição do fator vii lìquida, para inativar vìrus em uma composição do fator vii lìquida, e para eliminar em alto nìvel a presença de vìrus ativos em uma composição do fator vii lìquida
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
DK0891420T4 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
ATE351901T1 (de) Neue methoden und interferon defiziente substrate zur vermehrung von viren
DK1820853T3 (da) Rekombinant influenzavirus til vacciner og genterapi
BR9712544A (pt) Inibidores de proteases de serina, particularmente protease ns3 do vìrus hapatite c
AU2003248535A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
AU2003301959A1 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
ATE503764T1 (de) Inhibitoren des hepatitis-c-virus
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
ATE346035T1 (de) Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease
WO2007044024A3 (en) Recombinant influenza vectors with tandem transcription units
UY27614A1 (es) Formulaciones estabilizadas de adenovirus
DE602005023342D1 (en) S (porcine reproductive und respiratory syndrome) von schweinen
AR248045A1 (es) Procedimiento para producir un virus de avipox recombinante, un cultivo de celulas eucariotica, una vacuna y para expresar la totalidad o parte de una proteina heterologa, secuencia de transferencia
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
HK1129608A1 (en) Antiviral method
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
SG142300A1 (en) Promoters for expression in modified vaccinia virus ankara
AU2003234342A8 (en) Ablated slam-dependent entry
AR124384A1 (es) Parapoxvirus modificado que tiene inmunogenicidad aumentada
WO2021247953A3 (en) Compositions and methods for treating virus infection
ATE534410T1 (de) Verfahren zur inaktivierung von viren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)